Observational studyBlood advances2026

Pomalidomide for hereditary hemorrhagic telangiectasia: after trial longitudinal assessment study (PATH-HHT ATLAS).

Ellen Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.